Colour Online: See the article online to view Figs. 1, 3, 5 and 6 in colour.
A decade of proteomics studies of glaucomatous neurodegeneration
Version of Record online: 16 FEB 2014
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PROTEOMICS - Clinical Applications
Focus on Proteomics and the Eye
Volume 8, Issue 3-4, pages 154–167, April 2014
How to Cite
Tezel, G. (2014), A decade of proteomics studies of glaucomatous neurodegeneration. Prot. Clin. Appl., 8: 154–167. doi: 10.1002/prca.201300115
- Issue online: 13 APR 2014
- Version of Record online: 16 FEB 2014
- Accepted manuscript online: 10 JAN 2014 01:51PM EST
- Manuscript Accepted: 30 OCT 2013
- Manuscript Received: 28 OCT 2013
- National Eye Institute, Bethesda, MD. Grant Numbers: R01 EY013813, R01 EY017131
Glaucoma is a leading cause of blindness; however, limited understanding of the molecular mechanisms involved in optic nerve degeneration hinders the development of improved treatment strategies. Proteomics techniques that combine the protein chemistry, MS, and bioinformatics offer the opportunity to shed light on molecular mechanisms so that new treatment strategies can be developed for immunomodulation, neuroprotection, neurorescue, neuroregeneration, and function gain in glaucoma. The proteomics technologies also hold great promise for biomarker discovery, another important goal of glaucoma research. As much as developing new treatment strategies, molecular biomarkers are strongly needed for early diagnosis of glaucoma, prediction of its prognosis, and monitoring the responses to new treatments. It is now a decade that the proteomics analysis techniques have been using to move glaucoma research forward. This review will focus on valuable applications of proteomics in the field of glaucoma research and highlight the power of this analytical toolbox in translational and clinical research toward better characterization and improved treatment of glaucomatous neurodegeneration and discovery of glaucoma-related molecular biomarkers.